公开(公告)号：EP1276493B1

公开(公告)日：2004-09-29

申请号：EP01925259.2

申请日：2001-04-12

申请人： The University of British Columbia ,  Chemokine Therapeutics Corporation

发明人： SALARI, Hassan ,  MERZOUK, Ahmed ,  ARAB, Lakhdar ,  TUDAN, Christopher, R. ,  SAXENA, Geeta ,  EAVES, Connie, J. ,  CASHMAN, Johanne ,  CLARK-LEWIS, Ian

IPC分类号： A61K38/10 ,  C07K14/52

CPC分类号： C07K14/522 ,  A61K38/195

公开(公告)号：EP1286684A2

公开(公告)日：2003-03-05

申请号：EP01931279.2

申请日：2001-05-09

申请人： THE UNIVERSITY OF BRITISH COLUMBIA ,  Chemokine Therapeutics Corporation

发明人： TUDAN, Christopher, R. ,  MERZOUK, Ahmed ,  ARAB, Lakhdar ,  SAXENA, Geeta ,  EAVES, Connie, J. ,  CASHMAN, Johanne ,  CLARK-LEWIS, Ian ,  SALARI, Hassan

IPC分类号： A61K38/10 ,  A61K38/16 ,  A61P35/00 ,  A61P37/00

CPC分类号： A61K38/1709 ,  A61K38/10 ,  A61K48/00 ,  C07K14/4703 ,  C07K14/522 ,  C12N5/0647 ,  C12N2501/21

摘要： In accordance with various aspects of the invention, CXCR4 antagonists may be used to treat hematopoietic cells, such as progenitor or stem cells, to promote the rate of cellular multiplication, self-renewal, proliferation or expansion. CXCR4 antagonists may be used therapeutically to stimulate hematopoietic stem/progenitor cell multiplication/self-renewal.

公开(公告)号：EP1286684B1

公开(公告)日：2004-04-28

申请号：EP01931279.2

申请日：2001-05-09

申请人： THE UNIVERSITY OF BRITISH COLUMBIA ,  Chemokine Therapeutics Corporation

发明人： TUDAN, Christopher, R. ,  MERZOUK, Ahmed ,  ARAB, Lakhdar ,  SAXENA, Geeta ,  EAVES, Connie, J. ,  CASHMAN, Johanne ,  CLARK-LEWIS, Ian ,  SALARI, Hassan

IPC分类号： A61K38/10 ,  A61K38/16 ,  A61K38/19 ,  A61P35/00 ,  A61P37/06

CPC分类号： A61K38/1709 ,  A61K38/10 ,  A61K48/00 ,  C07K14/4703 ,  C07K14/522 ,  C12N5/0647 ,  C12N2501/21

摘要： In accordance with various aspects of the invention, CXCR4 antagonists may be used to treat hematopoietic cells, such as progenitor or stem cells, to promote the rate of cellular multiplication, self-renewal, proliferation or expansion. CXCR4 antagonists may be used therapeutically to stimulate hematopoietic stem/progenitor cell multiplication/self-renewal.

公开(公告)号：EP1276493A2

公开(公告)日：2003-01-22

申请号：EP01925259.2

申请日：2001-04-12

申请人： The University of British Columbia ,  Chemokine Therapeutics Corporation

发明人： SALARI, Hassan ,  MERZOUK, Ahmed ,  ARAB, Lakhdar ,  TUDAN, Christopher, R. ,  SAXENA, Geeta ,  EAVES, Connie, J. ,  CASHMAN, Johanne ,  CLARK-LEWIS, Ian

IPC分类号： A61K38/10

CPC分类号： C07K14/522 ,  A61K38/195

摘要： In accordance with various aspects of the invention, CXCR4 agonists, including SDF-1 polypeptides and SDF-1 polypeptide homologues, may be used in reducing the rate of hematopoietic cell multiplication. Methods of the invention may comprise administration of an effective amount of an CXCR4 agonist to cells selected from the group consisting of hematopoietic stem cells and hematopoietic progenitor cells. Cells may be treated in vitro or in vivo in a patient. A therapeutically effective amount of the CXCR4 agonist may be administered to a patient in need of such treatment. Patients in need of such treatments may include, for example patients requiring bone marrow or peripheral blood stem cell transplantation.

公开(公告)号：EP1061944B1

公开(公告)日：2004-01-28

申请号：EP99908703.4

申请日：1999-03-12

申请人： THE UNIVERSITY OF BRITISH COLUMBIA

发明人： CLARK-LEWIS, Ian ,  GONG, Jiang-Hong ,  DURONIO, Vincent, Dept.of Medicine, The University

IPC分类号： A61K38/21 ,  C07K14/52 ,  A61P35/00 ,  A61P37/00

CPC分类号： A61K38/1709 ,  C07K14/521 ,  C07K14/7158 ,  Y10S514/903

摘要： The invention provides a variety of therapeutic uses for CXCR4 antagonists. In various embodiments, CXCR4 antagonists may be used as therapeutically as follows, or to manufacture a medicament for such therapeutic treatments: reducing interferon gamma production by T-cells, treatment of an autoimmune disease, treatment multiple sclerosis, treatment of cancer, inhibition of angiogenesis. The invention provides corresponding methods of medical treatment, in which a therapeutic dose of a CXCR4 antagonist is administered in a pharmacologically acceptable formulation. Accordingly, the invention also provides therapeutic compositions comprising a CXCR4 antagonist and a pharmacologically acceptable excipient or carrier. The CXCR4 antagonists for use in the invention may be peptide compounds comprising a substantially purified peptide fragment, modified fragment, analogue or pharmacologically acceptable salt of SDF-1.

公开(公告)号：EP1061944A2

公开(公告)日：2000-12-27

申请号：EP99908703.4

申请日：1999-03-12

申请人： THE UNIVERSITY OF BRITISH COLUMBIA

发明人： CLARK-LEWIS, Ian ,  GONG, Jiang-Hong ,  DURONIO, Vincent,Dept.of Medicine,The University

IPC分类号： A61K38/21 ,  C07K14/52

CPC分类号： A61K38/1709 ,  C07K14/521 ,  C07K14/7158 ,  Y10S514/903

摘要： The invention provides a variety of therapeutic uses for CXCR4 antagonists. In various embodiments, CXCR4 antagonists may be used as therapeutically as follows, or to manufacture a medicament for such therapeutic treatments: reducing interferon gamma production by T-cells, treatment of an autoimmune disease, treatment multiple sclerosis, treatment of cancer, inhibition of angiogenesis. The invention provides corresponding methods of medical treatment, in which a therapeutic dose of a CXCR4 antagonist is administered in a pharmacologically acceptable formulation. Accordingly, the invention also provides therapeutic compositions comprising a CXCR4 antagonist and a pharmacologically acceptable excipient or carrier. The CXCR4 antagonists for use in the invention may be peptide compounds comprising a substantially purified peptide fragment, modified fragment, analogue or pharmacologically acceptable salt of SDF-1.